When was MOMA Therapeutics founded?

MOMA Therapeutics was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is MOMA Therapeutics located?

MOMA Therapeutics is headquartered in Cambridge, United States. It is registered at 80 Guest Street 5th Floor Brighton MA, 02135.

Who is the current CEO of MOMA Therapeutics?

Reid Huber of MOMA Therapeutics.

How many employees does MOMA Therapeutics have?

As of Feb 28, 2026, the latest employee count at MOMA Therapeutics is 53.

Is MOMA Therapeutics a funded company?

MOMA Therapeutics is a funded company, having raised a total of $236M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 15, 2020.

When was the latest funding round of MOMA Therapeutics?

MOMA Therapeutics' latest funding was a $***** Series B round on May 10, 2022, with participation from 10 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $2.52B in funding in 2026 to date.

Where does MOMA Therapeutics rank among its competitors?

MOMA Therapeutics ranks 754th amongst 3714 active competitors, of which 1283 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of MOMA Therapeutics?

MOMA Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

MOMA Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics targeting molecular machines that underlie disease. The company is developing precision medicines by targeting the molecular machines which are diverse proteins and enzymes which govern the cellular process. It is developing portfolio of programs targeting well-characterized drivers of cancer

Website: momatx.com
Social
Email ID: *****@momatx.com
Phone Number: +1 **********
Registered Address: 80 Guest Street 5th Floor Brighton MA, 02135

Key Metrics

Founded Year

2020

Location

Cambridge, United States

Stage

Series B

Total Funding

$236M in 2 rounds

Latest Funding Round

Series B, May 10, 2022, $*****

Investors

Goldman Sachs & 12 more

Ranked

754^th among 3714 active competitors

Employee Count

53 as on Feb 28, 2026

Similar Companies

Jazz Pharmaceuticals & 3545 more

View MOMA Therapeutics' full profile

MOMA Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MOMA THERAPEUTICS, INC. CIN: 83-4357140 , United States, Active	Apr 07, 2019	-	26 (As on Dec 31, 2020)	-

MOMA Therapeutics has raised a total funding of $236M over 2 rounds. Its first funding round was on Apr 15, 2020. Its latest funding round was a Series B round on May 10, 2022 for $*****. 10 investors participated in its latest round. MOMA Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of MOMA Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 10, 2022	2485124	Series B	1856039	1867763	9331072	8784859
Apr 15, 2020	7588905	Series A	8054514	9237264	Third Rock Ventures & 3 more	4319230

Access funding benchmarks and valuations. Sign up today!

View details of MOMA Therapeutics's funding rounds and investors

The founders of MOMA Therapeutics are Timur Yusufzai, Eva Nogales, Dorothee Kern and Johannes Walter. Reid Huber is the CEO of MOMA Therapeutics.

Here are the details of MOMA Therapeutics' key team members:

Timur Yusufzai: Founder of MOMA Therapeutics and founder of 1 other company.
Eva Nogales: Founder of MOMA Therapeutics.
Dorothee Kern: Founder of MOMA Therapeutics.
Johannes Walter: Founder of MOMA Therapeutics.
Reid Huber: CEO of MOMA Therapeutics.

View details of MOMA Therapeutics's Founder profiles and Board Members

MOMA Therapeutics' employee count trend

MOMA Therapeutics has 53 employees as of Feb 26. Here is MOMA Therapeutics's employee count trend over the years:

Employee count trend for MOMA Therapeutics

Uncover MOMA Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MOMA Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of MOMA Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
754th	MOMA Therapeutics 2020, Cambridge (United States), Series B	Developer of therapeutics targeting molecular machines that underlie disease	$236M	Curie.Bio, Nextech Invest & 11 others	49/100